HTG Molecular Diagnostics (HTGMQ) Form 3 HTG MOLECULAR DIAGNOSTICS / Byron Lawson ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Lawson Byron

(Last) (First) (Middle)

C/O HTG MOLECULAR DIAGNOSTICS, INC.

3430 E. GLOBAL LOOP

(Street)

TUCSON AZ 85706

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/23/2020

3. Issuer Name and Ticker or Trading Symbol
HTG MOLECULAR DIAGNOSTICS, INC [ HTGM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
SVP/Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	43,449	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	10/02/2022	Common Stock	931	2.15	D
Stock Option (right to buy)	(1)	01/31/2023	Common Stock	206	2.15	D
Stock Option (right to buy)	(1)	08/05/2023	Common Stock	1,862	2.15	D
Stock Option (right to buy)	(1)	03/19/2024	Common Stock	5,261	2.15	D
Stock Option (right to buy)	(1)	12/28/2024	Common Stock	1,862	12.89	D
Stock Option (right to buy)	(1)	11/24/2025	Common Stock	10,000	5.08	D
Stock Option (right to buy)	(2)	05/25/2026	Common Stock	5,000	2.83	D
Stock Option (right to buy)	(1)	01/31/2027	Common Stock	10,000	1.75	D
Stock Option (right to buy)	(3)	05/31/2027	Common Stock	5,000	3.46	D
Stock Option (right to buy)	(1)	07/25/2027	Common Stock	7,500	2.39	D
Stock Option (right to buy)	(4)	08/16/2028	Common Stock	30,000	3.4	D
Stock Option (right to buy)	(5)	08/06/2029	Common Stock	65,000	1.38	D
Stock Option (right to buy)	(5)	09/12/2029	Common Stock	35,000	0.8	D
Stock Option (right to buy)	(6)	01/07/2030	Common Stock	70,000	0.75	D

Explanation of Responses:

1. The shares subject to the stock option are fully vested.

2. The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after May 25, 2016.

3. The shares subject to the option will vest every three months in equal installments over four years beginning on August 31, 2017, such that the options is fully vested on May 31, 2021.

4. The shares vest in a series of sixteen (16) successive equal quarterly installments on the last day of each calendar quarter, commencing with the last day of the calendar quarter first occuring after August 16, 2018.

5. The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on September 30, 2019, such that the stock option is fully vested on August 31, 2021.

6. The shares will vest in equal monthly installments over a two-year period with the first vesting occurring on January 31, 2020, such that the stock option is fully vested on December 31, 2021.

Remarks:

	/s/ Shaun D. McMeans, Attorney-in-Fact	02/03/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.